Perflubron Emulsion Delays Blood Transfusions in Orthopedic Surgery

Author:

Spahn Donat R.1,van Brempt Ronald2,Theilmeier Gregor3,Reibold Jan-Peter4,Welte Martin5,Heinzerling Hartmut6,Birck Katrin M.7,Keipert Peter E.8,Messmer Konrad9,

Affiliation:

1. Professor, Department of Anesthesiology, University Hospital Zürich, Zürich, Switzerland.

2. Assistant Professor, Department of Anesthesiology, University Hospital Leuven, Leuven, Belgium.

3. Assistant Professor, Department of Anesthesiology, University Hospital Münster, Münster, Germany.

4. Assistant Professor, Department of Anesthesiology, University Hospital Giessen, Giessen, Germany.

5. Associate Professor, Department of Anesthesiology, University Hospital Munich, Munich, Germany.

6. Clinical Research Manager, R. W. Johnson Pharmaceutical Research Institute, Zürich, Switzerland.

7. Director of Clinical Research, R. W. Johnson Pharmaceutical Research Institute, Zürich, Switzerland.

8. Program Director, Oxygen Carriers Development, Alliance Pharmaceutical Corporation, San Diego, California.

9. Professor for Experimental Surgery, and Director, Institute for Surgical Research, University of Munich, Munich, Germany. §§Members of the European Perflubron Emulsion Study Group are listed in Appendix 1.

Abstract

Background Fluorocarbon emulsions have been proposed as temporary artificial oxygen carriers. The aim of the present study is to compare the effectiveness of perflubron emulsion with the effectiveness of autologous blood or colloid infusion for reversal of physiologic transfusion triggers. Methods A multinational, multicenter, randomized, controlled, single-blind, parallel group study was performed in 147 orthopedic patients. Patients underwent acute normovolemic hemodilution with colloid to a target hemoglobin of 9 g/dl with an inspiratory oxygen fraction (FIO2) of 0.40. Patients were then randomized into one of four treatment groups after having reached any of the protocol-defined transfusion triggers including tachycardia (heart rate > 125% of posthemodilution rate or > 110 bpm), hypotension (mean arterial pressure < 75% of posthemodilution level or < or = 60 mmHg), elevated cardiac output (> 150% of posthemodilution level) or decreased mixed venous oxygen partial pressure (PVO2; < 38 mmHg). Treatments in the four groups were 450 ml autologous blood harvested during acute normovolemic hemodilution given at FO2 = 0.40; 450 ml colloid at FIO2 = 1.0; 0.9 g/kg perflubron emulsion with colloid (total = 450 ml) at FIO2 = 1.0; and 1.8 g/kg perflubron emulsion with colloid (total = 450 ml) at FIO2 = 1.0. The primary endpoint was duration of transfusion-trigger reversal. A secondary end-point was percentage of transfusion-trigger reversal. Results Perflubron emulsion was well tolerated with no serious adverse event attributed to drug treatment. Duration of reversal was longest in the 1.8 g/kg perflubron group (median, 80 min; 95% confidence interval, 60-100 min; P = 0.014 vs. autologous blood, P < 0.001 vs. colloid) followed by the 0.9 g/kg perflubron group (median, 59 min; 95% confidence interval, 40-90 min), the autologous blood group (median, 55 min; 95% confidence interval, 30-70 min) and the colloid group (median, 30 min; 95% confidence interval, 27-60 min). Percentage of reversal was also highest in the 1.8 g/kg perflubron group (97%; P < 0.001 vs. autologous blood; P = 0.014 vs. colloid), followed by 0.9 g/kg perflubron (82%), colloid (76%), and autologous blood (60%). Conclusions Perflubron emulsion (1.8 g/kg) combined with 100% oxygen ventilation is more effective than autologous blood or colloid infusion in reversing physiologic transfusion triggers.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Anesthesiology and Pain Medicine

Reference36 articles.

Cited by 164 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. In searching for perfect blood substitute. Creation and application of perftorane;Khirurgiya. Zhurnal im. N.I. Pirogova;2024

2. Simultaneous Inhibition of Thrombosis and Inflammation Is Beneficial in Treating Acute Myocardial Infarction;International Journal of Molecular Sciences;2023-04-15

3. Rapamycin Perfluorocarbon Nanoparticle Mitigates Cisplatin-Induced Acute Kidney Injury;International Journal of Molecular Sciences;2023-03-23

4. Artificial red blood cells;Nanotechnology for Hematology, Blood Transfusion, and Artificial Blood;2022

5. Oxygent™, a Perfluorochemical-Based Oxygen Therapeutic for Surgical Patients;Blood Substitutes and Oxygen Biotherapeutics;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3